The factor H (FH) protein (also known as ptH globulin) is the main regulator of the complement alternative pathway. It exhibits multivalent binding sites to the complement component C3b, and polyanions and one binding site to sialic acid and cell surfaces. These multiple binding sites confer to FH a decay-accelerating factor activity in the fluid phase as well as at the cell surface. A defect in FH activity or a FH protein deficiency triggers chronic inflammation and tissue injury, leading to various disorders impacting the kidney or the eye. In contrast, some pathogens, as well as cancer cells, develop various strategies to bind FH and thereby subvert a complement attack. We focus on the functions of FH, and review the main pathological conditions in which FH is involved. Since the pathogenesis is elusive, appropriate FH dosage in biological fluids and FH gene analysis may help in improving understanding of such diseases.
The factor H (FH) protein, originally identified as 1H globulin in 1965 (l), is a 155,000 dalton single polypeptide chain which negatively regulates the complement cascade. FH controls the complement component 3 (C3) and modulates many of its functions. In this review, we describe FH physiology and especially its biological functions. We are also interested in the main diseases in which FH is involved and in diagnostic tests which may be relevant in clinics.
Factor H:from gene(s) to protein(s) expression and regulation
The human FH gene, mapped to chromosome I both in humans and mice, is located in the regulator of complement activation (RCA) gene cluster in 1q32 (2) . Northern-blot analyses of human liver mRNA report two other mRNAs, which are alternative-splicing-variants ofFH mRNA, encoding respectively the factor H-like 1 (FLH-1; 43,000 Da) and another protein (37,000 Da), which is less known (3) . In addition, five FH allelic variants, located close to the FH gene in the RCA gene cluster (4), encode for FH related-proteins (FHR1 to FHR5).
The FH protein is a 155,000 Da single polypeptide chain composed of twenty short consensus repeats (SCR) (5) . Structural studies on the flexibility and size of FH suggest that FH SCR domains are bent back upon themselves. Moreover, the peptidic sequence and length of SCR domains influence the interaction between FH and multivalent ligands.
FH (as FHL-1) is constitutively produced by the liver but other cells can produce FH (monocytes, keratinocytes, fibroblasts, oligodendrocytes or Classical Pathway Activated C1 v. BUDE ET AL.
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C3bBb3b generates active fragment C3b which, in association with complement factor B, forms the alternative C3 convertase, C3bBb. C3bBb is itselfa protease, and it cleaves C3 to form C3b, generating a positive feedback loop for C3 activation. The positive feedback loop is negatively regulated by complement factor H (FH), which displaces factor Bb from the C3bBb andpromotes the proteolytic inactivation ofC3b by complementfactor I (not shown).
various ocular tissue cell types), The plasma concentration of FH protein in adults is 443± 106 ug/rnl. with a normal range of 242 to 759 ug/ml. During inflammation, the synthesis of FH protein is up-regulated by IFNy in a dose-dependent manner.
Regulation ofcomplement activation
The main FH (and FHL-l) function is to regulate the complement alternative pathway ( Fig. 1 ). In this pathway, the complement component C3b is the first protein produced by the C3 cleavage. The C3b complement component binds the factor B (FB) to constitute the alternative C3 convertase (C3bBb) and to amplify its own formation. Then, the FH regulates the C3bBb convertase production, The inhibitory effect of FH on C3bBb production is a dual effect. FH acts as a cofactor offactor I to split C3b in iC3b, stopping C3bBb production. Second, FH competes with FB through the three binding sites for C3b (SCRl-4, SCR6-10 and SCR16-20), resulting in a decrease ofC3bBb (6) .
FH exerts its complement regulatory function in the fluid phase but also on the tissue surface (5) . While the C3bBb dissociation induced by FH is quick in the fluid phase, its removal from the cell surface is highly dependent on the presence of C3b. FH affinity for C3b bound to the cell surface is increased by the presence of polyanions such as heparin and sialic acid because of the presence of three binding sites for heparin (SCR7, SCRB and SCRI9-20) and one for sialic acid (SCRI6-20) on FH (7) . Therefore, polyanion-bearing cells promote FH binding to C3b instead of its interaction with FB/C3b, thereby protecting cells from alternative pathway complement attack. Most host cells are said to have "non-activator"surfaces because of the presence of a polyanion instead of foreign cell membranes, which lack this polyanion. However, some pathogens or cancer cells use this system to protect themselves from complement attack, which is an important way for pathogenesis to occur.
Immune cell response regulation during inflammation
C-reactive protein (CRP) and FH act jointly to restrain the side effect of inflammation. CRP promotes elimination of the damaged cells by phagocytosis, and FH limits the extent oftissue injury promoted by a complement attack. Moreover, FH is also involved in phagocytosis. First, the FH recruited by CRP at the surface of the damaged cells enhances the uptake of apoptotic cells by macrophages, and second, FH may help in immune cell recruitment (8) . L-selectin and aMJ32 (CD II b/CD18) are indeed ligands for FH, allowing its adhesion, especially on monocytes and neutrophils. In addition, FH binds to endothelial cells and favors adhesion of phagocytes to the vascular wall in order to recruit cells to the inflammation site. Furthermore, FH could act as a cherno-attractant for macrophages and may promote their phagocytic activity by enhancing their respiratory burst. FH is thereby a great antiphlogistic protein due to its capability ofinhibiting complement and the recruitment of phagocytic cells.
Factor H and infectious states
Microbial pathogens promote multiple strategies to subvert host innate and adaptive immunity (9) . Group B streptococci may exhibit outer membrane proteins (OMP) interacting with FH, thus providing complement resistance. Many studies of these OMPs indicate that each pathogen family develops its own OMP system which may differ even within the same microbial pathogen family (10) (11) .
The pathogenesis of the pathogen Borrelia burgdorferi has been widely studied because of its resistance to complement. Complement susceptibility among these strains is correlated with human complement-dependent phagocytosis and depends on their abilities to fix FH and FHL-l (12) . Many studies indicate that FH binding depends on the presence of complement-regulator-acquiring proteins (CRASP) (13) (14) .
Other microbial OMPs have been identified as FH binding proteins (15) . OMPs bind to FH on SCR, mimicking FH recruitment by the host. Moreover, all of these OMPs have been widely studied to develop novel therapeutic approaches and vaccines.
Factor H and cancer
As pathogens, tumor cells promote their own pathogenesis in several ways, especially through resistance to immune responses such as complement attack. Malignant cells may exhibit polyanions on their surface, and thus are capable of binding to the fluid phase FH (or FHL-l), resulting in "nonactivator cells", and expression of functional FH or FHL-I on several malignancy-derived cell lines has been reported. Indeed, some lung cancer cell lines cells secrete FH and to a lesser extent, FHL-l, and have been reported to be resistant to complement in vitro (16) . A mouse model grafted with stably FH siRNA transfected lung cancer cell line cells showed that FH inhibition significantly decreases tumor growth in vivo (16) . Analyses of patient samples also indicate that FH is probably involved in neoplasm pathogenesis. Immunohistochemistry studies performed on colon tumor (17) biopsies highlight FH and FHL-I. Moreover FH and FHL-l protein expression is higher in liver metastases than in primary sites of colorectal cancer, demonstrating that FH may promote tumor invasion. Soluble FH and/or FHL-l are also detected in biological fluids from bladder cancer patients (18) indicating that FH may be a useful marker for evaluating tumor development.
Factor H and renal diseases
The membranoproliferative glomerulonephritis type II (MGPN II) is a severe kidney disease also known as dense-deposit disease. Analyses by immunofluorescence staining indicate that the deposits within the lamina densa of the glomerular basement membrane are made up of C3. Most patients are positive for an autoantibody, the plasma C3 nephritic factor (C3NeF), directed against the alternative complement pathway C3 convertase, named C3bBb. C3NeF increases the half-life of the C3bBb and protects it from FH-mediated inactivation (19) . Exogenous FH infusion in FH-deficient mice decreases C3 deposition within the glomerular basement membrane and also restores plasma C3 regulation (20) . FH dysfunction, or absence, may be explained by various mutations occurring in the corresponding gene which lead to the retention of FH in the endoplasmic reticulum (21) or to a defective FH form which interacts weakly with C3b. Thus, FH abnormalities may rather exacerbate than directly induce MGPN II, which has already been initiated by the appearance of C3NeF.
Hemolytic-uremic syndrome (HUS) IS a thrombotic microangiopathy of kidney disease characterized by severe hemolytic anemia, thrombocytopenia, and acute renal failure. In contrast to typical HUS, atypical HUS (aHUS) is not triggered by a Shiga-like toxin produced by an infectious agent and does not manifest with diarrhea. The majority of aHUS cases are associated with genetic alterations occurring in a complement protein encoding gene such as factor I, CD46 (Membrane Cofactor Protein, MCP) or FH. A website database (www.FH-HUS.org) has been created and recently updated to present all mutations and single nucleotide polymorphisms described for these three genes (22) . More than 50 aHUS associated mutations in FH gene have been described, and their inheritance is often heterozygous. As a consequence, the common binding site to C3b, polyanions, and endothelial cells is altered, and FH decay-accelerating factor activity on the cell surface is impaired (23) . Moreover, alteration of the binding FH to platelets occurs, leading to their activation through complement deposition (24) .
Anti-FH autoantibodies are reported in the serum of patients (6-10%) with aHUS whereas no abnormality in the FH encoding gene or protein plasma level is observed (25) . These FH autoantibodies are directed against the SCR 15-20 domain and especially the SCR19-20 domain (26), so plasma FH activity is only slightly decreased whereas the cell surface regulatory function may be profoundly impaired. If the autoantibody level is decreased in the' patient fluid phase by plasma exchange therapy, the plasma C3 level is increased and clinical parameters are improved (27) , indicating that these autoantibodies are really involved in aHUS pathogenesis. Nevertheless, no study has yet shown a correlation between each described autoantibody and the severity of the disease.
To conclude, aHUS often results from mutation occurring in the FH encoding gene leading to a deficient FH or a defective FH activity. However, those mutations are not sufficient to allow the disease to develop. Therefore, aHUS is probably a multifactor disease.
Factor H and age-related macular degeneration
Age-related macular degeneration (AMD) is the most common cause of progressive but irreversible loss of vision in elderly people. The loss of central field vision resulting from AMD is attributable to the progressive destruction of the retina's central region (macula). Several susceptibility genes have been identified. Among them, the FH missense mutation which is commonly associated with AMD. Mutated FH and FHL-l bind less efficiently glycosaminoglycan and CRP, exhibited by an injured retinal cell surface resulting in cell surface complement activation and then formation of the MAC. Several studies report that patients with AMD exhibit an increased systemic complement activation compared to healthy patients, as shown by elevated C3a-desArg (28), C3d (29) plasma levels but normal FH levels. This suggests that AMD is a systemic disease with only local manifestations. Some evoke a correlation between FH haplotypes and systemic complement activation (30) but others contradict these results (29) . Mutated FH is clearly involved in local macular disease but its implication in systemic AMD disease remains ambiguous.
Factor H and Alzheimer sdisease
Alzheimer's disease is a common illness ofelderly people. It is a degenerative, terminal and incurable disease triggering memory loss and dementia. It is characterized by extracellular brain deposits of amyloid A~associated with inflammation related proteins on vessel walls. The involvement of FH in Alzheimer's disease is controversial (31) (32) and not clearly defined. However, the plasma FH level may reflect the disease because patients with Alzheimer's disease have elevated plasma FH levels positively correlated with the hippocampal metabolism, a biological marker reflecting cognitive decline (33) (34) . Even if the explanation for the increased level of FH remains misunderstood, experimental data supports the evidence that plasma FH must be considered as an important biomarker which may help in diagnosis of Alzheimer's disease and in predicting its progression.
Factor H and rheumatoid arthritis
Rheumatoid arthritis is a human autoimmune disease characterized by chronic inflammation of the synovial joints, leading to progressive destruction of cartilage and bones. Its aetiology and pathogenesis remain incompletely understood but, as with many autoimmune diseases, complement activation has been noted and an FH defect could be involved in the disease pathogenesis. However, some studies indicate that FH polymorphism is not associated with the disease (35) . Others show that FH is detectable in synovial fluid at a lower concentration compared to plasma. This may be explained by an increased permeability of the altered synovial membrane, allowing the supply of synovial fluid to plasma FH. Nonetheless synovial fibroblasts are able to secrete FH and especially FHL-I under INFy or dexamethasone stimulation (36) . In addition, synovial fibroblasts have the ability to bind FH and FHL-l to their surface, and as expected, surface bound FH and FHL-l protect these cells against complement-mediated lysis (37) . Therefore, neither FH nor FHL-l is involved in the rheumatoid arthritis pathogenesis but protect the synovial joints against inflammation. This protective effect is indeed increased by treatment (36) .
Diagnostic tests for complementfactor H in clinics
Common immunochemical methods can be used in most laboratories to quantify FH, such as radioimmunodiffusion (RID) and ELISA techniques. Currently, commercial RID assay kits for FH give reliable results on serum or plasma (38) . Regarding ELISA, one assay has been standardized and validated to perform diagnostic procedures for FH analysis (39) . However, most other studies usually use in-house ELISA methods. Studies using ELISA dosage of FH in urine or ascites have shown that FH could be used as a non-invasive biomarker for assessment of kidney injury, and bladder and ovarian cancer. In addition, serum measurement of FH detects approximately 25% of patients with mutations in the FH gene.
Consequently, genetic analyses are required and performed using denatured HPLC, single-strand conformation polymorphism, or direct sequencing. Although inexpensive, these first two techniques are not sensitive and do not reveal the position of FH mutation, so PCR sequencing is required. The FH gene, like many complement regulatory genes, is tightly linked to the RCA gene cluster on chromosome lq32. Genomics duplications arising in this cluster result in a high degree of sequence identity between the gene encoding FH and the genes encoding the five factor H-related proteins (FHRI through 5) (40) . Predisposition to gene conversion events and genomic rearrangements are due to these large genomic duplications. One study shows that significant genomic rearrangement in FH results in a hybrid gene in which exons 1 to 21 are derived from FH, and exons 22 and 23 from FHL-I (40) . These genomic rearrangements would not be picked by genomic sequencing using FH specific primers and because of the lack of FH exons 22 and 23 on one allele, the specific primer would amplify only exons 22 and 23 of FH on the normal allele.
Finally, FH autoantibodies have been detected by ELISA in a small percentage ofpatients presenting aHUS (between 6 to 11%) (25) . No anti-FH antibody has been found in patients with autoimmune disorders. These autoantibodies influence the binding of FH to the C3bBb convertase, thereby compromising FH activity in vivo (25) .
CONCLUSIONS
The FH protein is the main regulatory protein of the complement alternative pathway. Efficient in the fluid phase and on the cell surface, FH maintains complement homeostasis and prevents tissue damage. Some cancer cells secrete FH and, like some pathogens, have the ability to bind fluid phase FH to their surface. Subsequently, those cells subvert the host complement and are able to invade the host organism. In contrast, a defect in FH or an FH v.BUHE ET AL. deficiency triggers chronic inflammation. Associated with other pathologic events, FH abnormalities may induce diseases such as aHUS, MPGN II or AMD. Although complement activation is also involved in Alzheimer's disease and rheumatoid arthritis, FH polymorphisms are not associated with these diseases. However, most FH mutations abort FH binding to the cell surface and FH losses its surface decay-accelerating activity, so host cells are not protected from complement attack, leading to pathogenesis. FH is detectable in the biological fluids of numerous cancers. Therefore, this complement regulation protein is a biomarker which may help to diagnose a cancer or evaluate disease progression.
